Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yong Hoon | - |
dc.contributor.author | Her, Ae-Young | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Choi, Byoung Geol | - |
dc.contributor.author | Choi, Se Yeon | - |
dc.contributor.author | Byun, Jae Kyeong | - |
dc.contributor.author | Kang, Dong Oh | - |
dc.contributor.author | Jang, Won Young | - |
dc.contributor.author | Kim, Woohyeun | - |
dc.contributor.author | Baek, Ju Yeol | - |
dc.contributor.author | Choi, Woong Gil | - |
dc.contributor.author | Kang, Tae Soo | - |
dc.contributor.author | Ahn, Jihun | - |
dc.contributor.author | Park, Sang-Ho | - |
dc.contributor.author | Park, Sung Hun | - |
dc.contributor.author | Hong, Ji Yeon | - |
dc.contributor.author | Park, Ji Young | - |
dc.contributor.author | Lee, Min-Ho | - |
dc.contributor.author | Choi, Cheol Ung | - |
dc.contributor.author | Park, Chang Gyu | - |
dc.contributor.author | Seo, Hong Seog | - |
dc.date.accessioned | 2021-09-10T05:23:39Z | - |
dc.date.available | 2021-09-10T05:23:39Z | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 2251-6581 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18613 | - |
dc.description.abstract | Background and purpose Rare comparative studies investigated the relationship between combination therapy of antihypertensive drugs and the incidence of new-onset diabetes mellitus (NODM). The aim of this study was to evaluate which combination therapy, calcium channel blocker (CCB) with angiotensin converting enzyme inhibitor (ACEI) or CCB with angiotensin II type 1 receptor blocker (ARB), is best in reducing/preventing the development of NODM during 4-year follow-up periods in non-diabetic hypertensive Korean patients. Materials and methods Finally, a total of 1221 consecutive hypertensive patients without a history of diabetes mellitus who had been prescribed CCB were retrospectively enrolled and divided into the two groups, an ACEI group (combination CCB with ACEI, n = 251) and an ARB group (combination CCB with ARB, n = 970). The primary endpoint was NODM, defined as a fasting blood glucose >= 126 mg/dL or hemoglobin A1c >= 6.5%. Secondary endpoint was major adverse cardiac events (MACE) defined as total death, non-fatal myocardial infarction (MI) and percutaneous coronary intervention (PCI). Results After propensity-score matched (PSM) analysis, two propensity-matched groups (243 pairs, n = 486, C-statistic = 0.696) were generated. During 4-year follow-up periods, there were similar incidence of NODM (Hazard ratio [HR]; 1.198, 95% confidence interval [CI]; 0.591-2.431, P = 0.616), MACE (HR; 1.324, 95% CI; 0.714-2.453, P = 0.373), total death, MI and PCI between the two groups after PSM analysis. Conclusion CCB with ACE or CCB with ARB combination strategies are equally acceptable in hypertensive Korean patients regarding the occurrence of NODM. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BioMed Central | - |
dc.title | Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1007/s40200-020-00521-4 | - |
dc.identifier.scopusid | 2-s2.0-85085114294 | - |
dc.identifier.wosid | 000523402400001 | - |
dc.identifier.bibliographicCitation | Journal of Diabetes and Metabolic Disorders, v.19, no.1, pp 405 - 413 | - |
dc.citation.title | Journal of Diabetes and Metabolic Disorders | - |
dc.citation.volume | 19 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 405 | - |
dc.citation.endPage | 413 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | JOINT NATIONAL COMMITTEE | - |
dc.subject.keywordPlus | ANTIHYPERTENSIVE DRUGS | - |
dc.subject.keywordPlus | CARDIOVASCULAR MORBIDITY | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | 7TH REPORT | - |
dc.subject.keywordPlus | GLUCOSE | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | MELLITUS | - |
dc.subject.keywordPlus | SYSTEM | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Angiotensin converting enzyme inhibitor | - |
dc.subject.keywordAuthor | Angiotensin II type 1 receptor blocker | - |
dc.subject.keywordAuthor | Calcium channel blocker | - |
dc.subject.keywordAuthor | Diabetes mellitus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.